Fig. 1From: Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholdsa Trend of crude DALY rate per 100,000 based on the diseased group from 2000 to 2016, group 1 included communicable, maternal, neonatal and nutritional diseases, NCDs (non-communicable disease). b The mean of health expenditure per capita (PPP $2011 international) from 2000 to 2016 in 176 countriesBack to article page